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Abstract
Background: The prognosis of patients with gastrointestinal stromal tumor (GIST) after the failure of standard
therapies is poor with supportive care alone. Guidelines recommend clinical trials, and patients with good
performance status following standard therapies are often eligible for phase I clinical trials of investigational
agents; however, there are no detailed reports on the clinical outcomes of GIST patients enrolled in these
trials.
Methods: We retrospectively reviewed the clinical outcomes of 21 consecutive GIST patients who were
enrolled in one or more phase I clinical trials at a single center between March 2009 and November 2014.
Results: The median age was 57 years, and the median number of previous lines of standard chemotherapy
was three. Chemotherapy before enrollment in a phase I clinical trial included imatinib, sunitinib, and
regorafenib in 100, 95, and 43 % of patients, respectively. None of the patients achieved objective response.
Ten patients (47.6 %) were determined to be stable according to the Response Evaluation Criteria in Solid
Tumors; four of them (19.0 %) maintained their status for more than 24 weeks. Four patients achieved partial
response according to the Choi criteria. No dose-limiting toxicity was observed; however, severe adverse
events and grade 3 or higher toxicities were reported in one (4.8 %) and two patients (9.5 %), respectively.
Although no treatment-related deaths occurred, one patient (4.8 %) died within 30 days after the last drug
administration because of disease progression. The median progression-free survival was 1.9 months, and the
median overall survival time has not been reached.
Conclusions: Data suggested that phase I clinical trials were feasible and may provide prognostic benefits to
GIST patients after standard therapies, indicating that enrollment in these studies may provide a treatment
option for these patients.
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Background
Gastrointestinal stromal tumors (GISTs) are rare tumors
of the gastrointestinal tract, with an estimated number
of new cases per year being 4000–6000 in the United
States [1]; such tumors are predicted to affect approxi-
mately two cases per 100,000 individuals per year in
Japan [2]. Approximately 90 % of GISTs have a mutation
in c-kit or platelet-derived growth factor receptor alpha
(PDGFRA), which leads to constitutive activation of the
tyrosine kinase activity of KIT or PDGFRA as the main
carcinogenic mechanism of GIST, respectively [3, 4].
The remaining 10 % of GISTs are not associated with
these genomic alterations and are considered as the
wild-type GISTs [5, 6].
Imatinib, an oral receptor tyrosine kinase inhibitor
(TKI), is the first-line systemic chemotherapeutic agent
for metastatic or unresectable GIST [7–9]. Sunitinib is
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an oral multi-target receptor TKI that mainly binds to
vascular endothelial growth factor receptors (VEGFRs)
1, 2, and 3; its use improves the time to progression
(TTP) compared with the use of placebo after treatment
failure with imatinib (median TTP: 6.4 weeks with pla-
cebo vs. 27.3 weeks with sunitinib) [10–13]. Recently,
the use of regorafenib, which targets kinases involved in
angiogenesis, oncogenesis (i.e., KIT, Ret, and BRAF), and
tumor microenvironment [i.e., PDGFR and fibroblast
growth factor receptor (FGFR)], showed a statistically
significant improvement in progression-free survival
(PFS) compared with the use of placebo (median PFS,
4.8 and 0.9 months, respectively) [14]. Despite these
TKIs, the prognosis of GIST patients after the failure of
standard chemotherapy is still poor because reported
median PFS is less than 1 month with supportive care
(BSC) alone [14, 15]. Treatment options for these pa-
tients with a good performance status (PS) may include
clinical trials of investigational agents, TKI rechallenge,
and TKI continuation beyond progression according to
the guidelines of the National Comprehensive Cancer
Network (NCCN), the European Society for Medical
Oncology (ESMO) group [16, 17]. Similar recommenda-
tion was also reported in the Japanese guideline [18].
Disease-specific phase II or III trials may be preferred
options than all-comer phase I trials, if available, because
the primary objectives of phase I clinical trials are to
evaluate the safety and determine the maximum-
tolerated dose (MTD), pharmacokinetics (PK), and
pharmacodynamics (PD) [19]. However, disease-specific
phase II or III trials are not always available for rare can-
cers such as GIST. The safety and exploratory efficacy
analyses of phase I clinical trials have been reported in
some malignancies [20, 21]; however, the clinical out-
come of GIST patients in the all-comer phase I clinical
trials has not yet been reported. Here we retrospectively
evaluated the safety as well as exploratory efficacy of
phase I clinical trials in GIST patients at our institution
to rationalize the enrollment of GIST patients in phase I
clinical trials which was one of treatment options after
failure of the standard therapy.
Methods
Patients
We reviewed the electronic medical records of 21 con-
secutive GIST patients who were enrolled in phase I
clinical trials after failure of systemic chemotherapy at
our institution between March 2009 and November
2014. All patients having histologically-proven meta-
static/recurrent GIST diagnosed by a pathologist at our
institution had received standard chemotherapy at that
time and had experienced refractory diseases. Although
the phase I clinical trials open for GIST patients have
changed over time according to the trial availability at
our institution and the eligibility criteria, we proposed
the phase I clinical trials as one of therapeutic op-
tions for the patients who finished standard chemo-
therapy and could not be enrolled in phase II or III
trials for GIST because of availability. We proposed
phase I clinical trials among the trials being con-
ducted with respect to KIT/PDGFRA inhibitors, drugs
inhibiting downstream kinases of KIT and PDGFRA
tyrosine kinases, angiogenesis inhibitors, drugs which
have some evidences in sarcoma, and others. Finally,
patients were selected when they fulfilled the eligibil-
ity criteria. This retrospective study was conducted
under the approval of the institutional review board
according to the Japanese ethical guidelines for epide-
miologic research. Written informed consent was ob-
tained from all patients before enrollment in each
phase I clinical trial.
Methods and treatment evaluation
The following baseline characteristics were collected
from each patient: age, gender, Eastern Cooperative On-
cology Group (ECOG) PS, primary site, site of metasta-
sis, number of metastases, number of previous lines of
chemotherapy, previous treatment, and number and type
of enrolled phase I clinical trials. Safety profiles during
each phase I clinical trial, including dose-limiting tox-
icity (DLT), severe adverse events (SAEs) as defined in
each protocol, grade 3 or higher toxicities, and death
within 30 days after the last drug administration were
evaluated in accordance with each protocol using the
Common Terminology Criteria for Adverse Events ver-
sion 3.0 or 4.0. Tumor response was assessed by each in-
vestigator based on the Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.0 or 1.1 in each proto-
col. Response according to the Choi criteria, which con-
siders changes in both size and density of the tumor
based on computed tomography (CT), [21] was also
retrospectively assessed by two investigators (YN and
KS). Partial response (PR) according to the Choi criteria
was defined as a 10 % decrease in size or a 15 % de-
crease in tumor density (HU) based on enhanced CT
without the appearance of new lesions or obvious pro-
gression of nonmeasurable disease. If patients underwent
positron emission tomography (PET) during phase I
clinical trials, response was also retrospectively evaluated
according to the PET response criteria by European
Organization for Research and Treatment of Cancer
(EORTC) [22]. Information about the date of treatment
discontinuation, disease progression, last follow-up visit,
and death were also collected.
Statistical analysis
Objective response rate (ORR) was defined as the per-
centage of patients who achieved complete response
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(CR) or PR. Disease control rate (DCR) was defined as
the percentage of patients who achieved CR, PR, or
stable disease (SD) more than 24 weeks. PFS was defined
as the time from the start of treatment in a given phase
I clinical trial to disease progression or death from any
cause. Best PFS for each individual was defined as the
longest PFS in patients enrolled in more than one clin-
ical trial. OS was defined as the time from enrollment in
a phase I clinical trial to death from any cause. Patients
who were continuing the treatment or were lost to
follow-up were censored for PFS at the last follow-up
when they were known to be alive and free from disease
progression. Patients who were not dead or lost to
follow-up were censored for OS at the time when they
were last known to be alive. The median PFS and OS
were estimated by the Kaplan–Meier method. PFS of
subgroups according to response according to the
RECIST or Choi criteria and the number of previous
lines of chemotherapy were also compared using the
log-rank test. Hazard ratios (HRs) were calculated using
the Cox proportional hazards model with a single
covariate.
In comparison of the two sides, a P value of <0.05 was
considered statistically significant. The decision to dis-
continue treatment based on protocol was made by the
treating physician and based on the patient’s history,
clinical presentation, and imaging studies (response as-
sessment using the RECIST criteria). All statistical ana-
lyses were performed using IBM SPSS Statistics version
21 (IBM Corporation, Armonk, NY, USA).
Results
Patient characteristics
Twenty-one consecutive GIST patients participated in
16 phase I clinical trials between March 2009 and
November 2014 at our institution and were included
in this analysis. The median length of follow-up was
0.6 years (range 0.1–5.1) for all patients. A summary
of baseline patient characteristics is displayed in
Table 1. The median age was 57 years (range, 29–77),
and 14 patients (66.7 %) were males. Nineteen pa-
tients (90.5 %) were PS 0 and two (9.5 %) were PS 1
according to the ECOG criteria. The small intestine
(47.6 %) was the most common primary site, followed
by the stomach (33.3 %). The median number of pre-
vious lines of approved standard chemotherapy was
three (range, 2–5). Imatinib, sunitinib, and regorafenib
were administrated in 100, 95.2, and 42.9 % of pa-
tients, respectively. Genotype information was avail-
able only for four patients, two had KIT exon 11
mutations and the other two were wild-type GIST;
genotypes of the remaining 17 patients were unavail-
able. The median interval from initiation of the first-
line chemotherapy to the enrollment for phase I
clinical trial was 4.5 years (range, 1.4–10.1). Nine pa-
tients (42.9 %) were enrolled in two or more phase I
clinical trials. In the phase I clinical trials, 19 patients
(90.5 %) were treated with an investigational molecular
targeted agent as monotherapy, one patient (4.8 %)
was treated with a combination of an investigational
targeted agent and conventional cytotoxic agent (MEK
inhibitor in combination with gemcitabine), and one
patient (4.8 %) was treated with a cytotoxic agent as
monotherapy (a hypoxia-activated cytotoxic prodrug).
Main targets of these drugs according to the protocols
include heat-shock protein 90 (HSP90), breakpoint
cluster region-Abelson (BCR-ABL), PDGFR, activin
receptor-like kinase 1 (ALK1), mammalian target of
rapamycin (mTOR/p70S6), phosphoinositide-3 kinase
Table 1 Patient characteristics
n = 21 Percent
Age Median (range) 57 (29–77) -
Gender Male 14 66.7
Female 7 33.3
ECOG PS 0 19 90.5
1 2 9.5
Primary site Small intestine 10 47.6
Stomach 7 33.3
Others 4 19.0
Site of metastasis Liver 20 95.2
Peritoneum 10 47.6
Lymph node 6 28.6
Others 2 9.5
Number of metastases 0 1 4.8
1–2 15 71.4
≥3 5 23.8
Target lesion Yes 21 100
Previous surgery Yes 14 66.7
Number of previous
chemotherapy
Median (range) 3 (2–5) -
Previous treatment Imatinib 21 100
Sunitinib 20 95.2
Regorafenib 9 42.9
Interval from first line
chemotherapy to
starting for phase I trials





Type of phase I trials Targeting agentsa 19 90.5




aTarget: HSP90, BCR-ABL, PDGFR, ALK1, mTOR/p70S6, PI3K, HGF/c-MET, MEK,
TEM-1, PTK2, VEGFR+MET, and FGFR
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(PI3K), hepatocyte growth factor (HGF/c-MET), MEK,
tumor endothelial marker-1 (TEM-1), integrin, protein
tyrosine kinase-2 (PTK2), VEGFR with MET, and
FGFR.
Safety profiles
Safety profiles of the investigational drugs were evalu-
ated in all 21 patients (Table 2). Four patients were
excluded from DLT assessment cohort because of
early disease progression. Thus, 17 patients (81.0 %)
were assessed for DLT; none of the investigational
drugs were associated with DLT. One patient (4.8 %)
had SAE and was dead because of progressive disease.
Two patients (9.5 %) experienced adverse events
higher than grade 3; one patient developed neutro-
penia, whereas the other patient had increased serum
creatine kinase levels. Two patients (9.5 %) discontin-
ued protocol treatment during phase I clinical trials:
one because of persistent grade 2 thrombocytopenia
and the other because of vasculitis during infusion.
One patient was receiving protocol treatment on the
data cut-off day of March 2015. No treatment-related
deaths were observed. One patient (4.8 %) died within
30 days after the last drug administration because of
disease progression.
Tumor response
All patients were evaluated for tumor response. None of
the 21 patients included in this study achieved CR or PR
according to the RECIST. Ten patients (47.6 %) were de-
termined as SD; four of them (19.0 %) maintained SD
status for more than 24 weeks. Eleven patients (52.4 %)
were judged as PD. Therefore, RR and DCR were 0 and
19.0 %, respectively. All four patients with SD more than
24 weeks were treated with targeted agents (BCR-ABL,
ALK1, PI3K, and VEGFR with MET). However, we did
not examine gene alternations in four patients with long
SD. Therefore, we could not determine the relationship
between the target gene alterations and targeted agents.
A waterfall plot showed that eight patients (38.1 %)
showed some shrinkage from the baseline (Fig. 1).
Among them, four patients achieved PR according to
the Choi criteria. Two cases were evaluated by PET. One
patient with PR according to the Choi criteria showed
significant reduction in FDG uptake [partial metabolic
response (PMR): max SUV 33.5–24.4], and the other
case evaluated as PD according to the RECIST showed
increased FDG uptake and progressive metabolic re-
sponse (PMD: max SUV 6.9–13.3) according to the
EORTC PET response criteria [23].
Survival analysis
The overall median PFS in this study was 1.9 months,
and the median OS has not yet been reached (Fig. 2a,
b). Three-month PFS was estimated to be 33.3 %.
Among a total of 21 patients, patients with one or
two previous lines of chemotherapy (n = 7; median,
2.8 months) showed similar PFS to those with three
or more lines (n = 10; median, 1.5 months; HR, 0.839;
95 % CI, 0.296–2.376; P = 0.739) (Fig. 3a). Patients
showing SD according to the RECIST (n = 10; median,
3.9 months) had significantly longer median PFS than
Fig. 1 Waterfall plots of best response according to the RECIST
Table 2 Safety profiles
n = 21 Percent
Dose-limiting toxicity (DLT) 0 0
Severe adverse events (SAE) 1 4.8
Death (due to progressive disease) 1 4.8
Grade 3 or higher toxicity 2 9.5
Blood system disorders 1 4.8
Laboratory abnormalities 1 4.8
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those showing PD (n = 11; median, 0.93 months; P <
0.0001) and patients showing PR according to the
Choi criteria (n = 4; median, 5.9 months) also showed
statistically longer PFS than the other patients (total
n = 17; SD patients, n = 6 and PD patients, n = 11,
1.5 months; HR, 0.186; 95 % CI, 0.04–0.85; P = 0.03)
(Fig. 3b and c). The efficacy of phase I clinical trials
was compared among the first time phase I clinical trials
and thereafter using the data obtained from nine patients
who were enrolled in two or more phase I clinical trials,
and there was no difference in the median PFS (Fig. 4).
Discussion
In this study, we determined the clinical outcomes
of GIST patients enrolled in phase I clinical trials
and clarified values of phase I clinical trial for GIST
patients who finished the standard chemotherapy
and could not participate in disease-specific phase II
or III clinical trials. Although phase I clinical trials
are primarily designed to assess the safety and
recommended dose of investigational agents [19],
numerous trials evaluated and reported efficacy end-
points such as survival and tumor response [24],
which may facilitate the expanded cohort and subse-
quent Phase II or III trials. Thus, not only safety
evaluation but also overall clinical outcomes of each
malignancy or mutation in phase I clinical trials may
contribute to future development of drugs and clin-
ical trials. To the best of our knowledge, this study
is the first report on integrated analysis of GIST pa-
tients enrolled in multi-phase I clinical trials, al-
though there have been a few reports on phase I
clinical trials evaluating specific regimens for GIST
patients, in which estimated PFS was between 1.5
and 4.8 months [25–27].
In this study, the safety profiles of investigational drugs
were in agreement with the previously reported out-
comes in patients with other malignancies [28, 29]. Two
GIST patients (9.5 %) were withdrawn from a phase I
clinical trial because of toxicity or treatment refusal, and
there were no treatment-related deaths. In addition,
death within 30 days after the last drug administration
was observed in only one patient (4.8 %). These results
suggested that the overall safety profiles were acceptable.
Moreover, it is important to notice that nine patients
(42.9 %) had participated in two or more phase I clinical
trials by patients’ choice.
In this study, 47.6 % patients showed disease
stabilization with the median PFS of 1.9 months in all
patient populations and 3.9 months in patients who
achieved SD by RECIST. These results were comparable
to those reported by previous studies on imatinib rechal-
lenge or TKIs beyond progression, which showed a DCR
of 41–44.6 % and PFS of 1.8–2.4 months [15, 30, 31]. In
this study, the 3-month progression-free rate was
33.3 %; the value appears to be marginal in terms of
drug activities in the second-line therapy of sarcoma
[32]. We recognized neither PR nor CR; however, in the
third-line of sarcoma, responses were rarely observed in
the early clinical trials. These results suggest that GIST
patients may have some clinical benefits from partici-
pating in all comer phase I clinical trials with significant
safety as previously reported in other malignancies
[19–21, 23–28] and that phase I clinical trials may be one
of treatment options for patients with GISTs refractory to
the standard therapy.
Recent clinical trials in molecular targeted therapies
showed significant efficacy even under the setting of
phase clinical I trials. For example, BRAF inhibitors
were shown to improve OS and PFS in patients with
metastatic melanoma that had the BRAF V600E mu-
tation [33]. More recently, phase I clinical trials aim-
ing at immune checkpoint blockage with programmed
death 1 (PD-1) or its ligand (PD-L1) antibodies
Fig. 2 Kaplan–Meier plots of PFS and OS among all patients
included in this study. a The median PFS of all patients was
1.9 months. b The median OS has not been reached
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showed higher response rates in several malignancies
[34, 35]. Moreover, in the molecular-matching phase I
trials between genetic aberration and targeting agents,
matched patients had significant benefit, including
ORR and OS, compared with the non-matched ones
[36, 37]. Approximately 80 % of GIST patients have a
mutation in c-kit, and 10 % harbor a mutation in
PDGFRA. Therefore, development of TKIs of ima-
tinib, sunitinib, and regorafenib targeting both KIT
and PDGFRA tyrosine kinases is being vigorously ad-
vanced. However, activities of KIT-targeting drugs de-
creased with increased treatment lines. The wild-type
GIST, nearly 10 % of GISTs and poor responders to
imatinib, may have various genomic or epigenetic al-
terations in succinate dehydrogenase (SDH), neuro-
fibromatosis type 1 (NF1), BRAF, or RAS. Molecular
matching is suggested to be effective in SDH-deficient
GISTs [38–40] and NF1-GISTs [41]. Therefore, profil-
ing of genomic alterations may lead patients to right
phase I clinical trials, although we lacked genomic in-
formation of GIST in this study.
There are several limitations in this study. Given the inter-
val of 4.5 years from the first-line chemotherapy to enroll-
ment in a phase I clinical trial, GIST patients in this study
are a highly selected population, which may lead to selection
bias. The small sample size, single-center population, and
retrospective study may be limitations of this study. In this
retrospective study, patient selection, patient choice, and
patient-drug matching may be influenced by the availability
of investigational drugs and investigators’ opinions.
Conclusions
We showed that there were some clinical benefits for
GIST patients who enrolled in phase I clinical trials, and
overall safety profiles were acceptable. Our results sug-
gest that after the failure of conventional chemother-
apies, phase I trials might be one of treatment options
for refractory GISTs.
Fig. 4 PFS of patients enrolled in two or more phase I clinical trials based on RECIST. We used the data obtained from nine patients who were
enrolled in two or more phase I clinical trials. PFS of patients who underwent phase I clinical trial for the first time (n = 9; median, 3.6 months)
showed similar PFS compared with patients who underwent phase I clinical trial thereafter (n = 9; median, 1.9 months; HR, 0.598; 95 % CI,
0.23–1.57; P = 0.297)
(See figure on previous page.)
Fig. 3 Kaplan–Meier plots of PFS according to the RESIST and Choi criteria. a PFS in patients who received one or two previous lines of therapy
versus those who received three or more lines of therapy according to the RESIST. The PFS of patients who received one or two previous lines of
chemotherapy (n = 7; median, 2.8 months) showed similar PFS as patients who received three or more lines (n = 10, median, 1.5 months; HR,
0.839; P = 0.739). b PFS of patients with SD and PD based on RESIST. Patients showing SD by RECIST (n = 10; median, 3.9 months) had significantly
longer median PFS than those with PD (n = 11; median, 0.93 months; P < 0.0001). c PFS of patients with PR and SD/PD based on the Choi criteria.
Patients showing PR according to the Choi criteria (n = 4; median, 5.9 months) also showed statistically longer PFS than the other patients (total
n = 17; SD patients, n = 6 and PD patients, n = 11, 1.5 months; HR, 0.186; 95 % CI, 0.04–0.85; P = 0.03)
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